Third, we included more studies on lung cancer than on any other type of cancer, and more studies on anti-PD-1 inhibitors than on anti-PD-L1 inhibitors; the subgroup outcomes could be a result of these differences, which in turn makes it impossible to obtain exact conclusions. This evidence concerns the gene CD274 and lung cancer.